Female sex hormone responsive conditions

Indications & Dose:

Prevention of non-traumatic vertebral fractures in postmenopausal women of increased risk of osteoporosis.

BY MOUTH One 60mg tablet daily by oral administration, which may be taken at any time of the day without regard to meals. Calcium supplements are advised in women with a low dietary calcium uptake. 

Contraindications:

History of venous thromboembolic events (VTE), including deep vein thrombosis, pulmonary embolism and retinal vein thrombosis. Hypersensitivity to raloxifene or other ingredients in the tablet. Hepatic impairment including cholestrosis. Several general impairment. Unexplained uterine bleeding. 

Side Effects:

Cautions:

Precautions:

Risk for venous thromboembolic Risk of venous thromboembolic events of any aetiology. Event of an illness or a condition leading to a prolonged period of immobilisation.

Interaction:

Drugs
Cholestyramine: Decreased absorption and enterohepatic cycling of ralox i fene Clofibrate, indomethacin, naproxen, ibuprofen, diazepam,
diazoxide: Possible displacement of these highly protein-bound drugs
Warfarin: Decreased PT

Warnings:

Adverse Effects:

Lactations:

Special Precautions:

Counselling:

Side Effects Or Adverse Reactions:

CNS: Depression, insomnia
EENT: Sinusitis
GI: Nausea (8% incidence same as placebo), dyspepsia, vomiting.
GU: Vaginitis, leukorrhea
HEME: Thromboembolism
METAB: Weight gain, peripheral edema, decreased total cholesterol (6%), decreased LDL-C (11%), no effect on HDL-C or triglycerides
MS: Leg cramps (6%)
SKIN: Hot flashes (25%, vs 18% with placebo)

Patient And Carer Advice: